Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

  title={Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis},
  author={Jean Bourhis and Jens Overgaard and H{\'e}l{\`e}ne Audry and Kian K. Ang and Mi Saunders and Jacques Bernier and Jean Claude Horiot and Aur{\'e}lie Le Ma{\^i}tre and Thomas F. Pajak and Michael Poulsen and Brian O'Sullivan and Werner Dobrowsky and Andrzej Hliniak and Krzysztof Składowski and John H. Hay and Luiz H. J. Pinto and Carlo Fallai and Karen K. Fu and Richard J. Sylvester and Jean Pierre Pignon},
  journal={The Lancet},

Hyperfractionated or accelerated radiotherapy for head and neck cancer.

Comparison of the different types of altered radiotherapy suggests that hyperfractionation provides the greatest benefit, which was particularly efficient in reducing local failure, whereas the benefit on nodal control was less pronounced.

Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.

Patients with nonmetastatic NSCLC derived a significant OS benefit from accelerated or hyperfractionated radiotherapy; a similar but nonsignificant trend was observed for SCLC; as expected, there was increased acute esophageal toxicity.

A Randomized Prospective Study of Concurrent Chemo-Radiotherapy vs Accelerated Hyperfractionation in Advanced Cancer of Head and Neck.

The present study suggests that AHF should be preferred over CRT in locally advanced, unresectable, squamous cell head and neck cancer followed over three months non-treatment period.

Hyperfractionated radiotherapy with concurrent docetaxel for advanced head and neck cancer: a phase II study.

This modality is a valuable treatment option for the management of locally-advanced head and neck squamous cell cancer and should be considered for further study.

Hyperfractionated Accelerated Radiotherapy versus Conventional Fractionation Both Combined with Chemotherapy in Patients with Locally Advanced Head and Neck Carcinomas

There was no trend towards an improved efficacy of HART in comparison with CFRT in combination with CC, and the prognostic value of these pretreatment factors did not variate with the fractionation schedule used.

“ Hypofractionated Accelerated Radiotherapy Compared with Conventional Radiotherapy of Squamous Cell Carcinoma of Head and Neck with Concurrent Cisplatin ”

The hypofractionated regimen was associated with increased but tolerable acute and late morbidities, and the reduction in number of fractions and treatment time allows more efficient use of resources.

Prospective Study to Compare Conventional Radiotherapy with Hypofractionated Radiotherapy in Locally Advanced Carcinoma of Oral Cavity

Hypofractionated radiotherapy has a comparable response to conventional radiotherapy with slight more acute and late but manageable treatment related toxicity with significantly reduced treatment time.

The role of split-course hypofractionated palliative radiotherapy in head and neck cancer.

Hypofractionated accelerated radiotherapy in T1-3 N0 cancer of the larynx: A prospective cohort study with historical controls.

  • Z. SzutkowskiA. Kawecki P. Kukołowicz
  • Medicine
    Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
  • 2016



A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer.

Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers.

  • W. DobrowskyJ. Naude
  • Medicine
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2000

A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer.

Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial.

  • J. BourhisM. Lapeyre E. Benhamou
  • Medicine, Physics
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
The very accelerated RT regimen was feasible and provided a major benefit in locoregional control but had a modest effect on survival.

Impact of age on treatment effect in locally advanced head and neck cancer (HNC): Two individual patient data meta-analyses.

Treatment benefit decreases with increasing age, and patients aged 71+ did not benefit from Alt- RT nor from concomitant CT in MACH-NC, a study considering age as a potential modifier of the treatment effect.